Tranylcypromine

CHEMBL3989843 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

133.2 g/mol

LogP

1.5

Phase

4

Tranylcypromine is an irreversible, non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor that prevents the oxidative deamination of serotonin, norepinephrine, dopamine, and tyramine, increasing central monoamine levels and producing antidepressant and anxiolytic effects. It is used for treatment-resistant major depression, particularly atypical depression and social anxiety disorder with comorbid depression. Patients must follow strict dietary tyramine restrictions due to the risk of hypertensive crisis from impaired tyramine metabolism.

Molecular Weight

133.1900 g/mol

LogP

1.50

TPSA

26.00 Å²

Lipinski RO5

Pass

Therapeutic Areas

Bipolar Disorder Generalized Anxiety Disorder Leukemia Major Depressive Disorder Obesity Schizophrenia Stroke

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1

InChI

InChI=1S/2C9H11N/c2*10-9-6-8(9)7-4-2-1-3-5-7/h2*1-5,8-9H,6,10H2/t2*8-,9+/m10/s1

Molecular Formula

C9H11N

HBD / HBA

1 / 1

Rotatable Bonds

1

Heavy Atoms

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Tranylcypromine is an irreversible, non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor that prevents the oxidative deamination of serotonin, norepinephrine, dopamine, and tyramine, increasing central monoamine levels and producing antidepressant and anxiolytic effects. It is used for treatment-resistant major depression, particularly atypical depression and social anxiety disorder with comorbid depression. Patients must follow strict dietary tyramine restrictions due to the risk of hypertensive crisis from impaired tyramine metabolism.

Yes, Tranylcypromine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989843. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5530. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Tranylcypromine on PillFYI

Structure

Quick Data

Formula: C9H11N
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.